Akebia Therapeutics, Inc. (AKBA)

Market Cap	216.56M
Revenue (ttm)	200.53M
Net Income (ttm)	-98.47M
Shares Out	188.31M
EPS (ttm)	-0.53
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,129,046
Open	1.21
Previous Close	1.17
Day's Range	1.14 - 1.21
52-Week Range	0.24 - 1.84
Beta	0.82
Analysts	Strong Buy
Price Target	3.88 (+237.39%)
Earnings Date	Nov 2, 2023

About AKBA

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 20, 2014
• Employees: 204
• Stock Exchange: NASDAQ
• Ticker Symbol: AKBA

Financial Performance

In 2022, AKBA's revenue was $292.48 million, an increase of 38.19% compared to the previous year's $211.65 million. Losses were -$94.23 million, -66.59% less than in 2021.

Analyst Forecast

According to 2 analysts, the average rating for AKBA stock is "Strong Buy." The 12-month stock price forecast is $3.88, which is an increase of 237.39% from the latest price.

Price Target

$3.88

(237.39% upside)

Analyst Consensus: Strong Buy